Qualit-E-SpeakPharma-Insert
X

Find drug development pipeline and deal Updates information

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): OSE-127

            Therapeutic Area: Immunology

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Servier

            Deal Size: $21.4 million Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement March 17, 2020

            Details:

            In December 2016, OSE Immunotherapeutics granted Servier a two-step option agreement to acquire the exclusive worldwide license to develop and commercialize OSE-127.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): MaaT013

            Therapeutic Area: Immunology

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: SymBiosis

            Deal Size: $19.5 million Upfront Cash: Undisclosed

            Deal Type: Series B Financing February 05, 2020

            Details:

            The funding will continue the clinical development of the company's current pipeline as well as the extension to other indications in oncology.